We have recently reported the generation of an OVV armed with therapeutic genes such as miR-34a, Smac, and Beclin-1, which showed enhanced antitumor efficacy in hematologic malignancy [12, 13]. The gene discussed is BECN1; the disease is hematologic disorder.